🔗 Share this article

As the US proceeds with unprecedented adjustments to its immunization schedules, one figure appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines in the pandemic and has concentrated on potential deaths after Covid immunization in her short time at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Program

Public health authorities had intended to reveal major changes to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US out of alignment with many the world with no evidence for benefit. The planned update has been delayed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

A Shift at the Agency

The acting appointment could signify a strengthened alliance between the drug and vaccine centers as Høeg and Prasad consolidate power at the agency – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for discontinuing certain pediatric shot schedules in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Qualifications

Høeg has no apparent track record in medication creation, oversight or management, which has been typical for past directors of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for overseeing the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a large organization. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who led CBER have had.”

CDER has an enormous range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division authorizes numerous generic medications. There is also a biosimilars program, OTC medication office and so forth, and each of these have to be managed,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant administrative element to the position, which supervises more than 5,000 employees. “It is a huge administrative position, if you do it right,” she concluded.

Response and Disputed Programs

In response to questions about Høeg’s credentials and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a spokesperson stated that the “questions stem from inaccurate presumptions”.

“Her experience is consistent with the functions of her position,” the representative said, citing the months Høeg spent counseling the agency head on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial rapid therapy clearance system that reportedly worried her former heads. “By what process are these drugs being selected for this fast-track system? Who makes the calls?” Howard asked. “There’s a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards more relaxed oversight of all drugs, except for shots.”

Public Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if concerning, past, critics said. She published a research paper using unverified public submissions to assess the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the new administration included revising guidelines for new vaccines and discontinuing “non-essential” vaccines, she stated following the vote on a online show. At the agency, Høeg has according to sources proposed preventing adolescent males from getting Covid vaccines.

“She’s an complete ideologue who commences with her beliefs and tailors the evidence to retrofit the data in a very disingenuous, fraudulent manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|